Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | HRH2 | P25021 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | SCN1A | P35498 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19410760 | 0.98 | CYP3A4 (0.44) | OPRM1CYP3A4LMNACYP2D6ABCB11 | |
| SCHEMBL1976918 | 0.93 | CYP3A4 (0.48) | OPRM1CYP3A4LMNACYP2D6ABCB11 | |
| SCHEMBL2925260 | 0.93 | CYP3A4 (0.51) | OPRM1CYP3A4LMNACYP2D6ABCB11 | |
| SCHEMBL1684100 | 0.91 | OPRM1 (0.48) | OPRM1CYP3A4LMNACYP2D6ABCB11 | |
| Hydrochloric Acid SCHEMBL1282252 | 0.90 | OPRM1 (0.47) | OPRM1CYP3A4LMNACYP2D6ABCB11 | |
| SCHEMBL3637470 | 0.89 | CYP3A4 (0.47) | OPRM1CYP3A4LMNACYP2D6ABCB11 | |
| SCHEMBL1311224 | 0.87 | CYP3A4 (0.52) | OPRM1CYP3A4LMNACYP2D6ABCB11 | |
| Hydrochloric Acid SCHEMBL5729678 | 0.85 | CYP3A4 (0.53) | OPRM1CYP3A4LMNACYP2D6ABCB11 | |
| SCHEMBL14709851 | 0.85 | OPRM1 (0.46) | OPRM1CYP3A4LMNACYP2D6ABCB11 | |
| SCHEMBL6182684 | 0.84 | OPRM1 (0.43) | OPRM1CYP3A4LMNACYP2D6ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3941459-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025081019-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| US-11407729-B2 | Quinoline and quinazoline compounds and methods of use thereof | Stingray Therapeutics, Inc. (US) | 2022-08-09 | — | — | US | disclosed |
| US-11407729-B2 | Quinoline and quinazoline compounds and methods of use thereof | Stingray Therapeutics, Inc. (US) | 2022-08-09 | — | — | US | disclosed |
| EP-3941459-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Stingray Therapeutics, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| CN-113924092-A | Quinoline and quinazoline compounds and methods of use thereof | 斯汀格瑞治疗股份有限公司 | 2022-01-11 | — | — | CN | disclosed |
| US-11180497-B2 | Cyclic compounds as immunomodulating agents | ANGEX PHARMACEUTICAL, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11026936-B2 | Piperidinyl-propanone derivatives | MERCK PATENT GMBH (DE) | 2021-06-08 | — | — | US | disclosed |
| WO-2020190912-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Stingray Therapeutics, Inc. (US) | 2020-09-24 | — | — | WO | disclosed |
| US-20200299258-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2020-09-24 | — | — | US | disclosed |
| US-20090312372-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-17 | — | — | US | disclosed |
| US-20090312372-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-17 | — | — | US | disclosed |
| US-20090312372-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-17 | — | — | US | disclosed |
| US-20090306075-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306075-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306075-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-20080269288-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269288-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269288-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| WO-2008053194-A2 | PYRIDINE CARBOXAMIDES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11026936-B2 | Piperidinyl-propanone derivatives | PDK2, PDK3, PDK1 | OPRM1 3740/4885CYP3A4 1187/4885LMNA 1073/4885 |
| US-20090312372-A1 | CHEMICAL COMPOUNDS | HSD11B1, CYP11B1, CYP4A11 | OPRM1 1053/4885CYP3A4 30/4885LMNA 3702/4885 |
| US-20080269288-A1 | CHEMICAL COMPOUNDS | HSD11B1, CYP11B1, CYP4A11 | OPRM1 1053/4885CYP3A4 30/4885LMNA 3702/4885 |
| US-20200299258-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ENPP1, ENPP3, PDE7A | OPRM1 3988/4885CYP3A4 1413/4885LMNA 2675/4885 |
| US-20090306075-A1 | CHEMICAL COMPOUNDS | HSD11B1, CYP11B1, CYP4A11 | OPRM1 1053/4885CYP3A4 30/4885LMNA 3702/4885 |
| US-11180497-B2 | Cyclic compounds as immunomodulating agents | IDO1, IDO2, INMT | OPRM1 3327/4885CYP3A4 2639/4885LMNA 4768/4885 |
| US-11407729-B2 | Quinoline and quinazoline compounds and methods of use thereof | ENPP1, ENPP3, PDE7A | OPRM1 3988/4885CYP3A4 1413/4885LMNA 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.